Company
Pyxis Oncology
Charting a course to therapeutics for difficult-to-treat cancers
Also known as PYXIS ONCOLOGY, INC.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- Boston
- Legal name
- PYXIS ONCOLOGY, INC.
- pyxisoncology.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Pyxis Oncology has assembled a differentiated portfolio of clinical assets, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies, with the potential to further improve outcomes for patients with cancer.
Funding snapshot
- Total raised
- $194MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $172M2021-03-05
Funding rounds
- Round, 2021
- $172M2021-03-05, SEC form D sold, 38 investors
- Round, 2019
- $22M2019-06-28, SEC form D sold, 9 investors
Loading relationship preview